Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 1
1953 2
1955 2
1956 1
1957 1
1959 1
1961 7
1962 5
1963 6
1964 7
1965 9
1966 5
1967 15
1968 8
1969 7
1970 7
1971 4
1972 4
1973 8
1974 2
1975 3
1976 11
1977 6
1978 8
1979 17
1980 24
1981 8
1982 20
1983 24
1984 23
1985 33
1986 26
1987 27
1988 18
1989 34
1990 40
1991 21
1992 37
1993 34
1994 36
1995 54
1996 41
1997 42
1998 50
1999 54
2000 45
2001 47
2002 56
2003 67
2004 66
2005 59
2006 85
2007 95
2008 99
2009 118
2010 142
2011 144
2012 145
2013 145
2014 174
2015 172
2016 147
2017 136
2018 177
2019 176
2020 205
2021 177
2022 178
2023 146
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

3,447 results

Results by year

Filters applied: . Clear all
Page 1
CRISPR/Cas9.
Hatada I, Morita S, Horii T. Hatada I, et al. Among authors: morita s. Methods Mol Biol. 2023;2637:41-47. doi: 10.1007/978-1-0716-3016-7_3. Methods Mol Biol. 2023. PMID: 36773136
Secreted phospholipase A2 modifies extracellular vesicles and accelerates B cell lymphoma.
Kudo K, Miki Y, Carreras J, Nakayama S, Nakamoto Y, Ito M, Nagashima E, Yamamoto K, Higuchi H, Morita SY, Inoue A, Aoki J, Ando K, Nakamura N, Murakami M, Kotani A. Kudo K, et al. Among authors: morita sy. Cell Metab. 2022 Apr 5;34(4):615-633.e8. doi: 10.1016/j.cmet.2022.02.011. Epub 2022 Mar 15. Cell Metab. 2022. PMID: 35294862 Free article.
Regnase-1 Prevents Pulmonary Arterial Hypertension Through mRNA Degradation of Interleukin-6 and Platelet-Derived Growth Factor in Alveolar Macrophages.
Yaku A, Inagaki T, Asano R, Okazawa M, Mori H, Sato A, Hia F, Masaki T, Manabe Y, Ishibashi T, Vandenbon A, Nakatsuka Y, Akaki K, Yoshinaga M, Uehata T, Mino T, Morita S, Ishibashi-Ueda H, Morinobu A, Tsujimura T, Ogo T, Nakaoka Y, Takeuchi O. Yaku A, et al. Among authors: morita s. Circulation. 2022 Sep 27;146(13):1006-1022. doi: 10.1161/CIRCULATIONAHA.122.059435. Epub 2022 Aug 23. Circulation. 2022. PMID: 35997026
Cancer cell plasticity and MHC-II-mediated immune tolerance promote breast cancer metastasis to lymph nodes.
Lei PJ, Pereira ER, Andersson P, Amoozgar Z, Van Wijnbergen JW, O'Melia MJ, Zhou H, Chatterjee S, Ho WW, Posada JM, Kumar AS, Morita S, Menzel L, Chung C, Ergin I, Jones D, Huang P, Beyaz S, Padera TP. Lei PJ, et al. Among authors: morita s. J Exp Med. 2023 Sep 4;220(9):e20221847. doi: 10.1084/jem.20221847. Epub 2023 Jun 21. J Exp Med. 2023. PMID: 37341991 Free PMC article.
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC.
Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, Goto Y, Takeshita M, Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J, Yamamoto N, Nakanishi Y, Okamoto I. Yoneshima Y, et al. Among authors: morita s. J Thorac Oncol. 2021 Sep;16(9):1523-1532. doi: 10.1016/j.jtho.2021.03.027. Epub 2021 Apr 27. J Thorac Oncol. 2021. PMID: 33915251 Free article. Clinical Trial.
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.
Miyauchi E, Morita S, Nakamura A, Hosomi Y, Watanabe K, Ikeda S, Seike M, Fujita Y, Minato K, Ko R, Harada T, Hagiwara K, Kobayashi K, Nukiwa T, Inoue A; North-East Japan Study Group. Miyauchi E, et al. Among authors: morita s. J Clin Oncol. 2022 Nov 1;40(31):3587-3592. doi: 10.1200/JCO.21.02911. Epub 2022 Aug 12. J Clin Oncol. 2022. PMID: 35960896 Free PMC article. Clinical Trial.
International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1).
Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, Katai H, Watanabe M, Seto Y, Hoon Noh S, Kwang Yang H, Ji J, Baba H, Kitagawa Y, Morita S, Nishiyama M, Kodera Y; CONVO‐GC‐1 Study Group, Federation of Asian Clinical Oncology (FACO). Yoshida K, et al. Among authors: morita s. Ann Gastroenterol Surg. 2021 Oct 20;6(2):227-240. doi: 10.1002/ags3.12515. eCollection 2022 Mar. Ann Gastroenterol Surg. 2021. PMID: 35261948 Free PMC article.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: morita s. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
Akamatsu H, Toi Y, Hayashi H, Fujimoto D, Tachihara M, Furuya N, Otani S, Shimizu J, Katakami N, Azuma K, Miura N, Nishino K, Hara S, Teraoka S, Morita S, Nakagawa K, Yamamoto N. Akamatsu H, et al. Among authors: morita s. JAMA Oncol. 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758. JAMA Oncol. 2021. PMID: 33410885 Free PMC article. Clinical Trial.
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Kawashima Y, Fukuhara T, Saito H, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Seike M, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Kawashima Y, et al. Among authors: morita s. Lancet Respir Med. 2022 Jan;10(1):72-82. doi: 10.1016/S2213-2600(21)00166-1. Epub 2021 Aug 26. Lancet Respir Med. 2022. PMID: 34454653 Clinical Trial.
3,447 results